Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Mass Balance of Rosiptor in Healthy Subjects
NCT03185195Phase 1Completed
- Sponsor
- Aquinox Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rosiglitazone in interstitial cystitis (IC) and bladder pain syndrome (BPS), sponsored by Aquinox Pharmaceuticals. Primary endpoints: Absolute bioavailability (F) of AQX-1125, Mass balance recovery of total radioactivity in urine, faeces and all excreta and 3 more. Started Nov 2016; status: completed.
02
Drugs
rosiglitazone
03
Conditions
interstitial cystitis (IC)bladder pain syndrome (BPS)
Beyond the preview
Go deeper on NCT03185195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03185195.